KIT and gastrointestinal stromal tumor: The therapeutic effect of imatinib in GIST can also be achieved by activating NK cells through inhibiting the KIT signaling in DCs and thus promoting the cross-talk between DCs and NK cells, resulting in the secretion of IFNγ [113, 136, 175, 192, 194].